Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2015

At a glance

  • Drugs PAT SM6 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Patrys
  • Most Recent Events

    • 04 Feb 2015 According to a Patrys media release, results have been published in Haematologica.
    • 15 Apr 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 27 Mar 2014 Final results reported in a Patrys media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top